Heart failure drug less effective in real world
November 27, 2012 in Cardiology
A large study addressing the effectiveness and safety of aldosterone antagonist therapy for older heart failure patients has found notable differences between the drug's results in clinical trial vs. what occurs in actual practice, according to researchers at Duke Medicine.
Those differences have been noted anecdotally by doctors, and likely contributed to the slow adoption of aldosterone antagonists in clinical practice, but they had not been confirmed in a large study examining the drugs in real-world situations.
The Duke-led research, published Nov. 28, 2012, in the Journal of the American Medical Association, suggests that doctors should more closely model the types of patients and the procedures followed in clinical trials when prescribing drugs in practice.
"Understanding whether real-world effectiveness matches the efficacy of clinical trials is important to assure that we are implementing and providing the best care possible," said lead author Adrian F. Hernandez, M.D., MHS, a cardiologist and member of the Duke Clinical Research Institute. "We are in an era where drugs can be efficacious, and the question is can they be effective and safe in clinical practice as they're being used. That's where we find differences and need more comparative effectiveness studies."
Key efficacy trials decades ago reported impressive benefits of aldosterone antagonist therapy, but doctors have long had questions about its safety for older and sicker patients who may be at risk for retaining high levels of potassium in their blood – a potentially fatal condition known as hyperkalemia.
Hernandez and colleagues used Medicare data to identify older patients who had been hospitalized for heart failure or weak pumping action called reduced ejection fraction. Among more than 5,880 eligible patients, 1,070 were discharged with prescriptions for aldosterone antagonist drugs, which inhibit sodium reabsorption in the kidneys to lower fluid retention and, as a result, improve heart function.
The research team found fewer benefits associated with the drugs than had originally been reported. There was no difference in deaths or hospital readmissions for cardiovascular events between the patients who went on the aldosterone antagonists and patients who did not. Patients taking the drugs were, however, less likely to be readmitted to the hospital for heart failure. At the same time, they were at significantly higher risk of readmission for hyperkalemia.
The study suggests that aldosterone antagonists might have limited success in reducing deaths among older patients. Potential reasons include a lack of adherence to therapy, and improper dosing and monitoring in practical use.
"Patient populations, monitoring, and procedures in clinical trials are different than in normal practice," Hernandez said. "High-risk patients, women and members of minority groups are typically underrepresented in clinical trials, while clinical trial participants tend to adhere to therapy and follow-up tests."
Hernandez said the study's findings highlight the importance of conducting clinical trials that can be easily generalized to real-world practice. At the same time, better protocols for aldosterone antagonist therapy could be established for doctors to ensure appropriate patient selection, correct dosing, medication adherence and early follow-up visits to screen for hyperkalemia.
"We can't have a paradigm where we give a pill and say come back in three months," Hernandez said. "Developing systems that encourage optimal use and monitoring of aldosterone antagonist therapy may help ensure that the effectiveness of this therapy in clinical practice approaches what was achieved in clinical trials."
Journal reference:
Journal of the American Medical Association
Provided by
Duke University Medical Center
-
New data from studies bolsters case for using aldosterone antagonists in heart failure
Sep 19, 2011 |
not rated yet |
0
-
Recommended treatment for heart failure often underused
Oct 20, 2009 |
not rated yet |
0
-
USA and Europe different in aldosterone antagonists use in heart failure
Oct 21, 2009 |
not rated yet |
0
-
Tens of thousands of lives could potentially be saved by key heart failure therapies
Jun 06, 2011 |
not rated yet |
0
-
Combination ACE inhibitor therapy increases risk of kidney failure and death
Mar 21, 2011 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
Magnetic field and repulsion bewteen wires
3 hours ago
-
Enthalpy of reaction
9 hours ago
-
Harmonic oscillation problem -Dancing pot
9 hours ago
-
Ultracapacitor to power electromagnet?
10 hours ago
-
Confusion in Electro Statics
11 hours ago
-
simple gravity question
12 hours ago
- More from Physics Forums - Classical Physics
More news stories
Hospitals' cardiac arrest incidence and survival rates go hand in hand
Hospitals with the highest rates of cardiac arrests tend to have the poorest survival rates for those cases, new University of Michigan Health System research shows.
Cardiology
1 hour ago |
not rated yet |
0
Effect of fluid and sodium restrictions on weight loss among patients with heart failure
A clinical trial of 75 patients hospitalized with acute decompensated heart failure (ADHF) suggests that aggressive fluid and sodium restriction has no effect on weight loss or clinical stability at three days but was associated ...
Cardiology
1 hour ago |
not rated yet |
0
Which women should be screened for high cholesterol?
National guidelines recommend that at-risk women be screened for elevated cholesterol levels to reduce their chances of developing cardiovascular disease. But who is 'at risk?' The results of a study by investigators ...
Cardiology
5 hours ago |
not rated yet |
0
Atherosclerotic disease heredity mapped in nationwide study
Researchers at Lund University in Sweden have mapped the significance of heredity for common forms of atherosclerotic disease. No studies have previously examined whether different forms of the disease share heredity.
Cardiology
6 hours ago |
not rated yet |
0
Study finds improved CPR quality saves lives
(Medical Xpress)—Life-saving CPR has been a foundation of emergency medicine for more than a half century. But researchers at the University of Arizona College of Medicine-Phoenix are continuing to refine the procedure, ...
Cardiology
8 hours ago |
not rated yet |
0
Researchers develop model for better testing, targeting of malignant peripheral nerve sheath tumors
University of Minnesota Medical School researchers from the Masonic Cancer Center, University of Minnesota, in partnership with the University's Brain Tumor Program, have developed a new mouse model of malignant peripheral ...
Practice makes perfect? Not so much
Turns out, that old "practice makes perfect" adage may be overblown. New research led by Michigan State University's Zach Hambrick finds that a copious amount of practice is not enough to explain why people ...
Older prostate cancer patients should think twice before undergoing treatment
Older prostate cancer patients with other underlying health conditions should think twice before committing to surgery or radiation therapy for their cancer, according to a multicenter study led by researchers in the UCLA ...
New test better detects elephantiasis worm infection
A new diagnostic test for a worm infection that can lead to severe enlargement and deformities of the legs and genitals is far more sensitive than the currently used test, according to results of a field ...
Leading researchers report on the elusive search for biomarkers in Huntington's disease
While Huntington's disease (HD) is currently incurable, the HD research community anticipates that new disease-modifying therapies in development may slow or minimize disease progression. The success of HD research depends ...
Vermont becomes third US state to legalize assisted suicide
Vermont became on Monday the third US state to legalize physician-assisted suicide.